Clinical Handbook of Psychotropic Drugs

Quick and comprehensive information on psychotropic drugs for adults. - Accurate and up-to-date - Comparison charts help decision-making - Icons and full color - Available in print and online - Downloadable patient info sheetsMore about this book The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. - Independent, unbiased, up-to-date - Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options - Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug - Potential interactions and side effects summarized in comparison charts - With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek - Clearly written patient information sheets available for download as printable PDF filesThis book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs. New in this edition - Neuroscience-based nomenclature – added to product availability tables - Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso); also covers Qelbree (viloxazine extended-release capsules), the first new ADHD medication approved by the FDA in over a decade; as well as updates to SSRI use in pregnancy and antidepressant augmentation strategies - Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment - Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised - New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta (lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules)